Mossop

Factors associated with physical performance measures in a multiethnic cohort of older adults

*Gerontology and Geriatric Medicine* 2018; DOI:10.1177/2333721418778623

Clinical outcome of prostate cancer patients with germline DNA repair mutations: Retrospective analysis from an international study

*European Urology* 2018; 73(5):687-693

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition

*Cancer Discovery* 2017; 7(9):1006-1017

5-year patient-reported outcomes of bowel and urinary bother in the CHHiP trial (CRUK/06/016)

*Journal of Clinical Oncology* 2017; 35(Suppl 6):23

Do routine computed tomography scans detect early spinal cord compression in patients with castrate resistant prostate cancer? Implications for the PROMPTS trial

*Clinical Oncology* 2017; 29(3):e87

Effect of dose to the penile bbulb on erectile potency (EP) in prostate image-guided radiotherapy (IGRT)

*Clinical Oncology* 2017 29(3):e86

Diffusion-weighted imaging as a treatment response biomarker for evaluating bone metastases in prostate cancer: A pilot study

*Radiology* 2017; 283(1):168-177

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

*Lancet Oncology* 2016; 17(8):1047-1060

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

*Lancet Oncology* 2015; 16(16):1605-1616

DNA-repair defects and olaparib in metastatic prostate cancer

*New England Journal of Medicine* 2015; 373(18):1697-1708